The short answer is no—Big Pharma likely cannot move beyond amyloid fast enough to help the millions already living with dementia. The pharmaceutical industry has spent more than two decades and tens of billions of dollars pursuing amyloid-targeting treatments, building entire research programs, regulatory pathways, and manufacturing infrastructure around this single theory of Alzheimer’s disease. Pivoting away from an entrenched strategy takes time, money, and intellectual risk that most companies are reluctant to take simultaneously. The amyloid hypothesis—the idea that clearing amyloid-beta proteins from the brain reverses cognitive decline—has delivered incremental progress, not breakthroughs.
Lecanemab (Leqembi), approved by the FDA in 2023, slows cognitive decline by about 35% over 18 months in early-stage disease. That’s meaningful for someone diagnosed at 65, but it doesn’t restore lost memory or stop the disease. Meanwhile, tau tangles, neuroinflammation, vascular damage, and other pathologies continue unchecked. The industry’s reluctance to abandon amyloid reflects not just scientific caution but billions in sunk costs and a regulatory approval infrastructure that now favors amyloid-targeting drugs.
Table of Contents
- Why Is the Pharmaceutical Industry Still Focused on Amyloid?
- What Alternative Pathways Are Emerging, and How Far Behind Are They?
- How Long Do Clinical Trials for New Pathways Actually Take?
- What Do These Delays Mean for Family Caregivers and Patients?
- What Are the Common Pitfalls in the Transition Away from Amyloid?
- Examples of Non-Amyloid Therapies in Active Development
- The Infrastructure Barrier: Why Pharma Cannot Pivot Faster
- Frequently Asked Questions
Why Is the Pharmaceutical Industry Still Focused on Amyloid?
Regulatory approval for amyloid treatments has become a well-worn path. The FDA’s accelerated pathways for biomarker-confirmed Alzheimer’s disease mean that demonstrating amyloid clearance on a PET scan or cerebrospinal fluid test is often sufficient to gain conditional approval. Companies don’t have to show that removing amyloid improves memory or function anymore—they show it reduces amyloid and move forward. This reduces risk and accelerates timelines compared to waiting for large cognitive outcome trials, which can take 5–7 years. The economics also matter.
A company that has already spent $500 million developing an amyloid monoclonal antibody or BACE inhibitor has existing teams, manufacturing capacity, and regulatory relationships built around that mechanism. Pivoting to tau, inflammation, or vascular pathways means starting recruitment and development nearly from scratch. Even a pharmaceutical firm with substantial resources faces pressure from investors and boards to show near-term returns on past investments before chasing speculative alternatives. One consequence of this inertia is that combination therapies—pairing amyloid treatments with agents targeting other pathologies—remain underfunded relative to amyloid monotherapies. Eli Lilly, Biogen, and others are exploring combinations, but the regulatory and financial incentives still favor the single-mechanism approach. This delays the development of therapies that might actually arrest disease progression rather than merely slow it.
What Alternative Pathways Are Emerging, and How Far Behind Are They?
Tau pathology, not amyloid, appears more tightly correlated with cognitive decline and neurodegeneration in autopsy studies. Researchers have identified tau as the main culprit in frontotemporal dementia and as a secondary driver in Alzheimer’s. Several companies—including Eli Lilly, Biogen, and Axon Neuroscience—are developing tau-targeting monoclonal antibodies and other agents. However, tau trials are moving slower. The longest-running tau trial, Eli Lilly’s PENNON study, only recently reached interim analysis, and early signals suggest modest cognitive preservation at best. A tau therapy is unlikely to reach widespread clinical use before 2027–2028 at the earliest. Neuroinflammation is another major focus.
Microglial activation (inflammation driven by brain immune cells) correlates with neurodegeneration and cognitive decline. Eli Lilly’s GLP-1 receptor agonists (semaglutide and tirzepatide, known as Ozempic and Zepbound) are being studied in Alzheimer’s disease, partly because they reduce neuroinflammation and improve insulin sensitivity. These trials are ongoing, and early observational data is mixed. The risk here is that researchers will discover GLP-1 agonists work in a subset of patients (those with metabolic dysfunction) but fail in others, requiring patient selection and combination approaches that slow adoption. The limitation of pivoting to these alternatives is that we’re essentially repeating the amyloid playbook—spending years and billions on a single pathway, only to find it provides modest benefit in a subset of patients. There’s no guarantee that moving away from amyloid toward tau or inflammation will yield faster or better results. In fact, the amyloid hypothesis had the advantage of 20+ years of biomarker development and clinical validation. Tau and inflammation biomarkers are younger and less standardized, meaning trials will be harder to design and outcomes harder to compare across studies.
How Long Do Clinical Trials for New Pathways Actually Take?
Bringing any new Alzheimer’s therapeutic to market typically requires 10–15 years from initial discovery to FDA approval. Of that, Phase 3 clinical trials alone take 3–5 years to complete, enroll hundreds to thousands of participants, and generate cognitive outcome data robust enough to convince regulators and clinicians. Even with accelerated pathways, companies cannot ethically or scientifically rush through safety and efficacy testing. Consider the timeline for a tau monoclonal antibody in development today. The compound likely began preclinical work 5–7 years ago. Phase 1 safety trials took 1–2 years.
Phase 2, designed to show preliminary efficacy and optimal dosing, takes 2–3 years. Phase 3 is where most failures occur—the therapy that looked promising in a smaller group of 200 patients often shows no or minimal benefit in a large, diverse trial of 1,500 participants. If the Phase 3 fails, the program is shelved and the company must start again with a new compound or mechanism. Merck’s discontinued tau program is a cautionary example: the company invested heavily in tau targeting, ran large Phase 3 trials, and ultimately abandoned the approach when efficacy was insufficient. The practical consequence is that patients diagnosed with Alzheimer’s disease today will likely be in their late 70s or 80s by the time a non-amyloid therapy becomes widely available. For someone with mild cognitive impairment or early-stage dementia in 2026, the options are still amyloid-targeting treatments plus the same supportive care (cognitive training, exercise, medication for secondary symptoms) that existed five years ago. The timeline gap between “promising preclinical data” and “drug I can actually take” is a decade or more.
What Do These Delays Mean for Family Caregivers and Patients?
The practical reality is that people diagnosed today cannot wait for a better therapy to emerge. Lecanemab and the next generation of amyloid-targeting monoclonal antibodies (donanemab, scheduled for potential approval in 2024–2025) are the medications available now. They require intravenous infusions every 2–4 weeks, regular amyloid PET scans or tau PET scans to monitor for amyloid-related imaging abnormalities (brain microhemorrhages), and careful monitoring for infusion reactions. The burden is substantial—regular travel to infusion centers, imaging appointments, neurological evaluations—and the benefit is modest: slowing cognitive decline by 25–35% in early disease, not stopping it or reversing it. Comparing the current landscape to 10 years ago, the main change is that now there is a disease-modifying option where there was none.
That is progress. However, many patients and families expected Alzheimer’s research to yield cures or dramatic slowing of decline by 2025, and that expectation has not been met. The research community has underestimated the complexity of the disease, overestimated the power of targeting single pathways, and failed to build effective combination therapies at scale. For caregivers, the tradeoff is clear: a modest slowing of cognitive decline requires significant commitment to medical appointments, monitoring, and ongoing evaluation of whether the therapy is working for that specific patient. Not all patients tolerate amyloid-targeting antibodies—some develop amyloid-related imaging abnormalities, others show allergic reactions or infusion-related reactions, and many show no measurable cognitive benefit despite receiving the treatment. Understanding that alternative therapies are still 5–10 years away helps families make realistic decisions about pursuing or declining these early options.
What Are the Common Pitfalls in the Transition Away from Amyloid?
One major pitfall is the “single-pathway fallacy.” Researchers have assumed that if amyloid is involved in Alzheimer’s disease, removing amyloid will reverse cognitive loss. The flaw is that Alzheimer’s pathology is multifactorial—amyloid deposits may trigger tau accumulation, neuroinflammation, and vascular damage, but removing amyloid after decades of accumulated damage cannot undo tau tangles or regenerate dead neurons. This means that even a “successful” non-amyloid therapy may fail if it’s developed for patients in late stages of disease and tested alone rather than in combination with amyloid targeting. A second pitfall is the lack of early biomarker development for emerging pathways. Amyloid biomarkers (PET imaging, cerebrospinal fluid tests, blood tests) were developed and validated over 15+ years. When companies now try to measure tau or neuroinflammation, the biomarkers are less standardized, making it harder to select the right patients for trials and to interpret results. Blood tests for phosphorylated tau (p-tau) are improving, but tau PET imaging is expensive, limited to research centers, and not yet used in routine clinical practice.
This delays both trial efficiency and eventual clinical implementation. A third pitfall is that combination therapy development is underfunded relative to monotherapy development. The FDA’s regulatory and commercial incentives favor single-agent approvals. A company can approve an amyloid-targeting drug, immediately begin marketing it, and recoup investment. A combination of an amyloid drug plus a tau drug is more complex—both agents must be developed, both must show benefit in combination (not just individually), and the regulatory burden is higher. As a result, most early-stage disease patients are offered amyloid targeting first, then considered for experimental combination trials only if they decline or fail amyloid therapy. This sequential approach misses the opportunity to prevent disease progression before multiple pathways become simultaneously damaged.
Examples of Non-Amyloid Therapies in Active Development
Eli Lilly’s remternetug (an anti-tau monoclonal antibody) is one of the furthest along outside the amyloid space, with Phase 2 data showing modest slowing of cognitive decline in early symptomatic disease. The company also has combination trials pairing tau targeting with amyloid targeting in early-stage patients. However, remternetug requires intravenous infusions similar to anti-amyloid antibodies, and early data suggests efficacy may be even more modest than lecanemab.
Sage Therapeutics and other companies are exploring neuroinflammation-targeting agents, including microglial inhibitors and glia-modulating compounds. These are earlier in development—most are in Phase 1 or Phase 2—and their cognitive benefit is unproven. The potential advantage is oral dosing (no infusions required) and a novel mechanism that might work synergistically with amyloid targeting. The risk is that the first generation of anti-inflammatory Alzheimer’s drugs may fail to show cognitive benefit, delaying this entire field by years and redirecting investment back toward amyloid and tau.
The Infrastructure Barrier: Why Pharma Cannot Pivot Faster
The largest pharmaceutical companies have organized entire divisions around amyloid-targeting development. Biogen, once solely focused on multiple sclerosis and neurodegeneration, transformed itself into an amyloid company through partnerships with Eisai and acquisition of amyloid-focused biotech firms. Eli Lilly acquired Elan’s amyloid program and has devoted massive resources to building multiple anti-amyloid and now anti-tau antibodies. Roche/Genentech, AbbVie, and others have similar commitments. Pivoting this infrastructure—moving experienced scientists and clinicians from amyloid programs to tau, inflammation, or vascular programs—is possible but slow.
It requires admitting that past investments, while not wasted, did not yield the hoped-for outcome. It requires rebuilding regulatory expertise, manufacturing capacity, and clinical trial networks around new mechanisms. Smaller biotech companies can pivot faster because they have fewer invested programs, but they often lack the resources to run large, expensive Phase 3 trials. The result is an asymmetry: amyloid programs continue to receive the bulk of funding and infrastructure investment, while non-amyloid programs remain underfunded and slower to mature. For patients diagnosed in 2026, this infrastructure inertia means that the Alzheimer’s disease therapies available in 2030 will still be primarily amyloid-focused, with promising but unproven tau and inflammation-targeting options beginning to emerge.
Frequently Asked Questions
Is lecanemab the only FDA-approved disease-modifying treatment for Alzheimer’s disease?
As of 2026, lecanemab (Leqembi) and donanemab are the primary anti-amyloid monoclonal antibodies approved or pending approval by the FDA for early-stage Alzheimer’s disease. Both require intravenous infusions and regular monitoring. Aducanumab (Aduhelm) was approved in 2021 but later withdrawn due to questions about clinical benefit, making many clinicians and patients hesitant about anti-amyloid approaches.
When will tau-targeting drugs be available?
Tau-targeted therapies are in Phase 2 and Phase 3 trials as of 2026, with potential FDA approvals expected in 2027–2029 if efficacy is demonstrated. However, early data suggests the cognitive benefit may be modest, similar to or less than amyloid-targeting treatments.
Can I combine amyloid and tau treatments?
Combination trials are ongoing, but these therapies are not yet approved for simultaneous use in clinical practice. Some research centers offer combination therapy within clinical trials, but it is not standard of care.
Why hasn’t Big Pharma developed better Alzheimer’s treatments?
The underlying biology is more complex than researchers initially believed. Alzheimer’s disease involves multiple pathways (amyloid, tau, neuroinflammation, vascular damage, metabolic dysfunction) that may require simultaneous targeting to reverse cognitive loss. Single-mechanism therapies have proven sufficient only to slow decline modestly, not stop or reverse it. Additionally, late-stage disease (moderate to advanced dementia) is neurobiologically irreversible—these therapies can only work in early stages before neurons are destroyed.
Should I pursue amyloid-targeting treatment if I’m diagnosed with early Alzheimer’s disease?
This is a decision best made with a cognitive neurologist or dementia specialist. Lecanemab offers a 35% relative slowing of cognitive decline in early symptomatic disease, but it requires regular infusions, amyloid PET scans, and monitoring for side effects. Not all patients show measurable benefit, and some experience amyloid-related imaging abnormalities (microhemorrhages). Discuss your specific risk factors, preferences, and expected disease timeline with a specialist before deciding.
